{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:47:19Z","timestamp":1791082039557,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejps.2024.106808","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:22:33Z","timestamp":1716394953000},"page":"106808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure\u2013response approach"],"prefix":"10.1016","volume":"199","author":[{"given":"Haijun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-6058","authenticated-orcid":false,"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1617-3315","authenticated-orcid":false,"given":"Xiaoxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejps.2024.106808_bib0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS. J."},{"issue":"2","key":"10.1016\/j.ejps.2024.106808_bib0003","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.hepres.2005.09.006","article-title":"Pathology of nonalcoholic steatohepatitis","volume":"33","author":"Brunt","year":"2005","journal-title":"Hepatol. Res."},{"issue":"6","key":"10.1016\/j.ejps.2024.106808_bib0016","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model","volume":"37","author":"Ette","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106808_bib0009","unstructured":"FDA 2024: FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease. 2024; Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"issue":"3","key":"10.1016\/j.ejps.2024.106808_bib0007","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41591-023-02242-6","article-title":"Challenges and opportunities in NASH drug development","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.ejps.2024.106808_bib0012","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1038\/s41467-023-42162-0","article-title":"ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ejps.2024.106808_bib0014","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput. Methods Programs Biomed."},{"issue":"3","key":"10.1016\/j.ejps.2024.106808_bib0013","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2307\/2532087","article-title":"Nonlinear mixed effects models for repeated measures data","volume":"46","author":"Lindstrom","year":"1990","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.ejps.2024.106808_bib0008","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jceh.2021.06.015","article-title":"Saroglitazar for Nonalcoholic Fatty Liver Disease: a Single Centre Experience in 91 Patients","volume":"12","author":"Padole","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"4","key":"10.1016\/j.ejps.2024.106808_bib0002","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.ejps.2024.106808_bib0017","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1208\/s12248-009-9133-0","article-title":"Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions","volume":"11","author":"Savic","year":"2009","journal-title":"AAPS. J."},{"issue":"5","key":"10.1016\/j.ejps.2024.106808_bib0010","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000507231","article-title":"Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis","volume":"36","author":"Schattenberg","year":"2020","journal-title":"Visc. Med."},{"issue":"3","key":"10.1016\/j.ejps.2024.106808_bib0005","first-page":"213","article-title":"Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis","volume":"35","author":"Sinakos","year":"2022","journal-title":"Ann. Gastroenterol."},{"issue":"Suppl","key":"10.1016\/j.ejps.2024.106808_bib0001","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.ejps.2024.106808_bib0006","article-title":"Current, emerging, and potential therapies for non-alcoholic steatohepatitis","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejps.2024.106808_bib0004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejps.2024.106808_bib0011","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/13543784.2021.1900822","article-title":"Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study","volume":"30","author":"Zhu","year":"2021","journal-title":"Expert. Opin. Investig. Drugs"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724001209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724001209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T02:53:44Z","timestamp":1718247224000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724001209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":17,"alternative-id":["S0928098724001209"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106808","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure\u2013response approach","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106808"}}